Mithra will receive a ~$1.58M milestone & is expected to receive an additional ~$16.42M in regulatory & sales milestones along with tiered royalties on annual net sales
Searchlight is responsible for receiving & maintaining the regulatory approvals to market and distribute Donesta in the country. Both companies focus on providing innovative solutions to women by partnering on Myring, Estelle & Donesta
Donesta is the next-generation medicine that contains Estetrol to treat menopause symptoms. Mithra highlighted the promising topline safety results from the P-III trial of Donesta in North America where results will support marketing authorization filings in the US in H2’23 and in Canada in 2024
Ref: Businesswire | Image: Mithra
Related News:- Mithra Signs License Agreement with Searchlight Pharma for Donesta in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
